MYLAN-VERAPAMIL SR TABLET (EXTENDED-RELEASE)
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
15-01-2020
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
VERAPAMIL HYDROCHLORIDE
제공처:
MYLAN PHARMACEUTICALS ULC
ATC 코드:
C08DA01
INN (International Name):
VERAPAMIL
복용량:
120MG
약제 형태:
TABLET (EXTENDED-RELEASE)
구성:
VERAPAMIL HYDROCHLORIDE 120MG
관리 경로:
ORAL
패키지 단위:
100
처방전 유형:
Prescription
치료 영역:
MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS
제품 요약:
Active ingredient group (AIG) number: 0113846001; AHFS:
승인 상태:
APPROVED
승인 날짜:
2016-01-08
제품 특성 요약
1
PRODUCT MONOGRAPH
PR
MYLAN-VERAPAMIL
SR
verapamil hydrochloride sustained-release tablets, USP
120 mg, 180 mg and 240 mg
Antihypertensive Agent
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke ON
M8Z 2S6
Control No: 235062
Date of Revision: January 15, 2020
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................................
3
SUMMARY PRODUCT
INFORMATION………………………………………………..………………3
INDICATIONS AND CLINICAL USE
.......................................................................................................
3
CONTRAINDICATIONS
............................................................................................................................
4
WARNINGS AND PRECAUTIONS
...........................................................................................................
5
ADVERSE REACTIONS
...........................................................................................................................
11
DRUG INTERACTIONS
...........................................................................................................................
14
DOSAGE AND ADMINISTRATION
.......................................................................................................
24
OVERDOSAGE
.........................................................................................................................................
26
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................................
27
STORAGE AND STABILITY
...................................................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................................
32
PART II: SCIENTIFIC INFORMATION
.....................................................................................................
34
PHARMACEUTICAL INFORMATION
........
전체 문서 읽기
